

**Table S3. Associations between HbA1c and pre-ESRD mortality and ESRD – sensitivity analyses**

	<6%	6-6.9%	7-7.9%	8-8.9%	>9%
<b>Mortality*</b>	HR (95% CI)		HR (95% CI)	HR (95% CI)	HR (95% CI)
Exclude patients with baseline malignancy	1.31 (1.03, 1.66)	Ref	1.03 (0.84, 1.26)	1.01 (0.78, 1.32)	1.44 (1.11, 1.87)
Exclude events during first 6 months of follow up	1.28 (1.02, 1.60)	Ref	0.95 (0.78, 1.15)	0.99 (0.76, 1.28)	1.51 (1.17, 1.94)
<b>ESRD*</b>	SHR (95% CI)		SHR (95% CI)	SHR (95% CI)	SHR (95% CI)
Exclude patients with baseline malignancy	0.69 (0.38, 1.23)	Ref	0.74 (0.48, 1.15)	0.55 (0.31, 0.98)	1.17 (0.74, 1.86)
Exclude events during first 6 months of follow up	0.66 (0.36, 1.21)	Ref	0.91 (0.59, 1.40)	0.60 (0.34, 1.08)	1.21 (0.75, 1.96)

\*Adjusted for age, race, sex, coronary artery disease, congestive heart failure, cerebrovascular disease, peripheral vascular disease, smoking, BMI group, use of angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs), statins and beta blockers, albumin, hemoglobin, eGFR and albuminuria. Estimates combine using MIanalyze on the 5 imputed datasets